ESR1 and breast cancer: Triple-negative breast cancer (TNBC) presents an aggressive subtype of breast cancer with inferior survival outcomes, as it lacks molecular biomarkers such as estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [1].